 | • レポートコード：MRC23Q36059 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、87ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥429,200 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥858,400 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の出血性脳卒中治療薬市場について調査・分析し、世界の出血性脳卒中治療薬市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（抗凝固剤、利尿剤、その他）、用途別セグメント分析（病院、薬局、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Novartis AG、Daiichi Sankyo Company、Zydus Cadila、F. Hoffmann-La Roche Ltd.、Boehringer Ingelheim International GmbH、Amneal Pharmaceuticals LLC、Teva Pharmaceutical Industries Ltd.、AstraZenica、Bristol-Myers Squibb Company、Johnson and Johnson Services, Inc.などが含まれています。 世界の出血性脳卒中治療薬市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、出血性脳卒中治療薬市場規模を推定する際に考慮しました。本レポートは、出血性脳卒中治療薬の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、出血性脳卒中治療薬に関するビジネス上の意思決定に役立てることを目的としています。 ・出血性脳卒中治療薬市場の概要 - 出血性脳卒中治療薬のタイプ別セグメント - 世界の出血性脳卒中治療薬市場規模：タイプ別分析（抗凝固剤、利尿剤、その他） - 出血性脳卒中治療薬の用途別セグメント - 世界の出血性脳卒中治療薬市場規模：用途別分析（病院、薬局、その他） - 世界の出血性脳卒中治療薬市場規模予測（2018年-2029年） ・出血性脳卒中治療薬市場の成長トレンド - 出血性脳卒中治療薬の地域別市場規模（2018年-2029年） - 出血性脳卒中治療薬市場ダイナミクス - 出血性脳卒中治療薬の業界動向 - 出血性脳卒中治療薬市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：抗凝固剤、利尿剤、その他 - 世界の出血性脳卒中治療薬のタイプ別市場規模（2018年-2023年） - 世界の出血性脳卒中治療薬のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院、薬局、その他 - 世界の出血性脳卒中治療薬の用途別市場規模（2018年-2023年） - 世界の出血性脳卒中治療薬の用途別市場規模（2024年-2029年） ・出血性脳卒中治療薬の地域別市場規模 - 北米の出血性脳卒中治療薬市場規模（2018年-2029年） - アメリカの出血性脳卒中治療薬市場規模（2018年-2029年） - ヨーロッパの出血性脳卒中治療薬市場規模（2018年-2029年） - アジア太平洋の出血性脳卒中治療薬市場規模（2018年-2029年） - 中国の出血性脳卒中治療薬市場規模（2018年-2029年） - 日本の出血性脳卒中治療薬市場規模（2018年-2029年） - 韓国の出血性脳卒中治療薬市場規模（2018年-2029年） - インドの出血性脳卒中治療薬市場規模（2018年-2029年） - オーストラリアの出血性脳卒中治療薬市場規模（2018年-2029年） - 中南米の出血性脳卒中治療薬市場規模（2018年-2029年） - 中東・アフリカの出血性脳卒中治療薬市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Novartis AG、Daiichi Sankyo Company、Zydus Cadila、F. Hoffmann-La Roche Ltd.、Boehringer Ingelheim International GmbH、Amneal Pharmaceuticals LLC、Teva Pharmaceutical Industries Ltd.、AstraZenica、Bristol-Myers Squibb Company、Johnson and Johnson Services, Inc. ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Hemorrhagic Stroke Drugs market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Hemorrhagic Stroke Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Hemorrhagic Stroke Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Hemorrhagic Stroke Drugs in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Hemorrhagic Stroke Drugs include Novartis AG, Daiichi Sankyo Company, Zydus Cadila, F. Hoffmann-La Roche Ltd., Boehringer Ingelheim International GmbH, Amneal Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., AstraZenica and Bristol-Myers Squibb Company, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Hemorrhagic Stroke Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hemorrhagic Stroke Drugs.
The Hemorrhagic Stroke Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Hemorrhagic Stroke Drugs market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hemorrhagic Stroke Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Novartis AG
Daiichi Sankyo Company
Zydus Cadila
F. Hoffmann-La Roche Ltd.
Boehringer Ingelheim International GmbH
Amneal Pharmaceuticals LLC
Teva Pharmaceutical Industries Ltd.
AstraZenica
Bristol-Myers Squibb Company
Johnson and Johnson Services, Inc.
Segment by Type
Anticoagulant
Diuretics
Others
Segment by Application
Hospital
Pharmacy
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hemorrhagic Stroke Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hemorrhagic Stroke Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Anticoagulant
1.2.3 Diuretics
1.2.4 Others
1.3 Market by Application
1.3.1 Global Hemorrhagic Stroke Drugs Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hemorrhagic Stroke Drugs Market Perspective (2018-2029)
2.2 Hemorrhagic Stroke Drugs Growth Trends by Region
2.2.1 Global Hemorrhagic Stroke Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Hemorrhagic Stroke Drugs Historic Market Size by Region (2018-2023)
2.2.3 Hemorrhagic Stroke Drugs Forecasted Market Size by Region (2024-2029)
2.3 Hemorrhagic Stroke Drugs Market Dynamics
2.3.1 Hemorrhagic Stroke Drugs Industry Trends
2.3.2 Hemorrhagic Stroke Drugs Market Drivers
2.3.3 Hemorrhagic Stroke Drugs Market Challenges
2.3.4 Hemorrhagic Stroke Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hemorrhagic Stroke Drugs Players by Revenue
3.1.1 Global Top Hemorrhagic Stroke Drugs Players by Revenue (2018-2023)
3.1.2 Global Hemorrhagic Stroke Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Hemorrhagic Stroke Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hemorrhagic Stroke Drugs Revenue
3.4 Global Hemorrhagic Stroke Drugs Market Concentration Ratio
3.4.1 Global Hemorrhagic Stroke Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hemorrhagic Stroke Drugs Revenue in 2022
3.5 Hemorrhagic Stroke Drugs Key Players Head office and Area Served
3.6 Key Players Hemorrhagic Stroke Drugs Product Solution and Service
3.7 Date of Enter into Hemorrhagic Stroke Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hemorrhagic Stroke Drugs Breakdown Data by Type
4.1 Global Hemorrhagic Stroke Drugs Historic Market Size by Type (2018-2023)
4.2 Global Hemorrhagic Stroke Drugs Forecasted Market Size by Type (2024-2029)
5 Hemorrhagic Stroke Drugs Breakdown Data by Application
5.1 Global Hemorrhagic Stroke Drugs Historic Market Size by Application (2018-2023)
5.2 Global Hemorrhagic Stroke Drugs Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Hemorrhagic Stroke Drugs Market Size (2018-2029)
6.2 North America Hemorrhagic Stroke Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Hemorrhagic Stroke Drugs Market Size by Country (2018-2023)
6.4 North America Hemorrhagic Stroke Drugs Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hemorrhagic Stroke Drugs Market Size (2018-2029)
7.2 Europe Hemorrhagic Stroke Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Hemorrhagic Stroke Drugs Market Size by Country (2018-2023)
7.4 Europe Hemorrhagic Stroke Drugs Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hemorrhagic Stroke Drugs Market Size (2018-2029)
8.2 Asia-Pacific Hemorrhagic Stroke Drugs Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Hemorrhagic Stroke Drugs Market Size by Region (2018-2023)
8.4 Asia-Pacific Hemorrhagic Stroke Drugs Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Hemorrhagic Stroke Drugs Market Size (2018-2029)
9.2 Latin America Hemorrhagic Stroke Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Hemorrhagic Stroke Drugs Market Size by Country (2018-2023)
9.4 Latin America Hemorrhagic Stroke Drugs Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hemorrhagic Stroke Drugs Market Size (2018-2029)
10.2 Middle East & Africa Hemorrhagic Stroke Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Hemorrhagic Stroke Drugs Market Size by Country (2018-2023)
10.4 Middle East & Africa Hemorrhagic Stroke Drugs Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis AG
11.1.1 Novartis AG Company Detail
11.1.2 Novartis AG Business Overview
11.1.3 Novartis AG Hemorrhagic Stroke Drugs Introduction
11.1.4 Novartis AG Revenue in Hemorrhagic Stroke Drugs Business (2018-2023)
11.1.5 Novartis AG Recent Development
11.2 Daiichi Sankyo Company
11.2.1 Daiichi Sankyo Company Company Detail
11.2.2 Daiichi Sankyo Company Business Overview
11.2.3 Daiichi Sankyo Company Hemorrhagic Stroke Drugs Introduction
11.2.4 Daiichi Sankyo Company Revenue in Hemorrhagic Stroke Drugs Business (2018-2023)
11.2.5 Daiichi Sankyo Company Recent Development
11.3 Zydus Cadila
11.3.1 Zydus Cadila Company Detail
11.3.2 Zydus Cadila Business Overview
11.3.3 Zydus Cadila Hemorrhagic Stroke Drugs Introduction
11.3.4 Zydus Cadila Revenue in Hemorrhagic Stroke Drugs Business (2018-2023)
11.3.5 Zydus Cadila Recent Development
11.4 F. Hoffmann-La Roche Ltd.
11.4.1 F. Hoffmann-La Roche Ltd. Company Detail
11.4.2 F. Hoffmann-La Roche Ltd. Business Overview
11.4.3 F. Hoffmann-La Roche Ltd. Hemorrhagic Stroke Drugs Introduction
11.4.4 F. Hoffmann-La Roche Ltd. Revenue in Hemorrhagic Stroke Drugs Business (2018-2023)
11.4.5 F. Hoffmann-La Roche Ltd. Recent Development
11.5 Boehringer Ingelheim International GmbH
11.5.1 Boehringer Ingelheim International GmbH Company Detail
11.5.2 Boehringer Ingelheim International GmbH Business Overview
11.5.3 Boehringer Ingelheim International GmbH Hemorrhagic Stroke Drugs Introduction
11.5.4 Boehringer Ingelheim International GmbH Revenue in Hemorrhagic Stroke Drugs Business (2018-2023)
11.5.5 Boehringer Ingelheim International GmbH Recent Development
11.6 Amneal Pharmaceuticals LLC
11.6.1 Amneal Pharmaceuticals LLC Company Detail
11.6.2 Amneal Pharmaceuticals LLC Business Overview
11.6.3 Amneal Pharmaceuticals LLC Hemorrhagic Stroke Drugs Introduction
11.6.4 Amneal Pharmaceuticals LLC Revenue in Hemorrhagic Stroke Drugs Business (2018-2023)
11.6.5 Amneal Pharmaceuticals LLC Recent Development
11.7 Teva Pharmaceutical Industries Ltd.
11.7.1 Teva Pharmaceutical Industries Ltd. Company Detail
11.7.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.7.3 Teva Pharmaceutical Industries Ltd. Hemorrhagic Stroke Drugs Introduction
11.7.4 Teva Pharmaceutical Industries Ltd. Revenue in Hemorrhagic Stroke Drugs Business (2018-2023)
11.7.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.8 AstraZenica
11.8.1 AstraZenica Company Detail
11.8.2 AstraZenica Business Overview
11.8.3 AstraZenica Hemorrhagic Stroke Drugs Introduction
11.8.4 AstraZenica Revenue in Hemorrhagic Stroke Drugs Business (2018-2023)
11.8.5 AstraZenica Recent Development
11.9 Bristol-Myers Squibb Company
11.9.1 Bristol-Myers Squibb Company Company Detail
11.9.2 Bristol-Myers Squibb Company Business Overview
11.9.3 Bristol-Myers Squibb Company Hemorrhagic Stroke Drugs Introduction
11.9.4 Bristol-Myers Squibb Company Revenue in Hemorrhagic Stroke Drugs Business (2018-2023)
11.9.5 Bristol-Myers Squibb Company Recent Development
11.10 Johnson and Johnson Services, Inc.
11.10.1 Johnson and Johnson Services, Inc. Company Detail
11.10.2 Johnson and Johnson Services, Inc. Business Overview
11.10.3 Johnson and Johnson Services, Inc. Hemorrhagic Stroke Drugs Introduction
11.10.4 Johnson and Johnson Services, Inc. Revenue in Hemorrhagic Stroke Drugs Business (2018-2023)
11.10.5 Johnson and Johnson Services, Inc. Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details